June 27, 2018 / 11:39 AM / a year ago

Global Blood Therapeutics' sickle cell disease drug succeeds in trial

June 27 (Reuters) - Global Blood Therapeutics Inc said on Wednesday its experimental drug met the main goal of a late-stage trial testing it in patients with sickle cell disease.

A statistically significant number of patients on the treatment, voxelotor, showed a rise in levels of hemoglobin - a protein in red blood cells that carries oxygen throughout the body - compared to a placebo.

The results were from the first phase of the late-stage trial, the company said. (Reporting by Manas Mishra and Tamara Mathias in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below